BETHLEHEM, Pa., March 23, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced today that it has submitted to the U.S. Food and Drug Administration ("FDA") an application for a ...

Nursing homes will be required to have Clinical Laboratory Improvement Amendments (CLIA) waivers to perform COVID-19 point-of-care tests. As a result, the Centers for Medicare & Medicaid Services is ...

The CLIA-waived CitoCBC® expands patient access to quick CBC results in physician offices, pharmacies, and home care, enabling data-driven diagnostics. CBC is one of the most commonly requested lab ...

Stockhead’s Tylah Tully looks at news from Lumos Diagnostics (ASX:LDX), who has submitted its application to the FDA for CLIA waiver approval for FebriDx, a rapid point-of-care diagnostic test to ...

MRS Allergy announces the availability of Clarity CoviBlock Covid19 IgM/IgG Antibody tests for point of care (POC) applications including the possibility of vaccine priority and verification.

The US Food and Drug Administration (FDA) has cleared a complete blood cell count (CBC) test that can be run in more healthcare settings, including physicians' offices, clinics, or other types of ...

Testing for those who have developed antibodies against the coronavirus can help tackle the ongoing COVID-19 pandemic. Now, a new study has identified all the antibody tests available for the ...

BiomarkerBase™ () has recently been updated to include every biomarker listed in a phase 3 or 4 clinical drug trial. This addition of over 170 new clinical biomarkers adds to the hundreds of existing ...